esophagus | Media Room | PressRelease.com

Press Release Jun 25, 2020

Cernostics Announces Blinded, Independent Validation of TissueCypher(R) Performance for Predicting Risk of Progression to Esophageal Cancer in Patients With Non-Dysplastic BE

Study further validates TissueCypher(R) as the first and only precision medicine test proven to provide actionable data for predicting patient progression to high-grade dysplasia and esophageal adenocarcinoma

Cernostics Announces Groundbreaking Data Demonstrating TissueCypher Performance for Predicting Risk of Progression to EAC in Patients With Non-Dysplastic BE

First-of-its-kind precision medicine test for esophageal pinch biopsies identifies high-risk, non-dysplastic BE patients that progress to EAC at rates higher than expert-confirmed LGD

TissueCypher® Further Validated to Accurately Risk Stratify Barrett's Esophagus Patients With Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences

Data presented at ACG, UEGW illustrates the fourth independent validation of TissueCypher performance for risk stratifying non-dysplastic Barrett's esophagus (NDBE) patients; expands indication for testing low-grade dysplasia (LGD)